Pfizer Price Increases Underscore Rebate Problem, HHS’ Hargan Says
Pfizer Price Increases Underscore Rebate Problem, HHS’ Hargan Says
$131.00
At December’s FDA/CMS Summit in Washington, Health and Human Services Secretary Eric Hargan used Pfizer’s recent price hike of 41 of its products as evidence that higher drug costs are a direct result of the rebate system, a viewpoint touted by the Trump administration in their quest to lower drug prices.
Publisher: Pinksheet
- Description
How do we fix high list prices? The Trump administration remains convinced that the answer lies in pointing the finger at the rebating system, and instituting changes to it. When Pfizer recently announced an increase in list prices for 10% of their drugs (41 in all), Health and Human Services Secretary Eric Hargan used it as evidence that changing the rebate system is the pathway to lowering drug costs overall. Read more about Hargan’s comments on the matter, made during December’s FDA/CMS Summit in Washington, in this essential Pink Sheet article.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fru... 
Sign up to the